The structure of the lowest electronic Rydberg state of CdAr complex determined by laser double resonance method in a supersonic jet-expansion beam

The lowest E1(3Sigma(+)) Rydberg state of the CdAr van der Waals (vdW) complex was investigated by means of an optical-optical double resonance (OODR) method of laser spectroscopy in conjunction with a free jet-expansion molecular beam. Two dye lasers were employed for the two-step excitation. The A0(+)(3Pi(+)) and B1(3Sigma(+)) states were used as intermediates in the excitation process from the X0(+)(1Sigma(+)) ground state. Two types of bound-bound excitation spectra of the E1<--A0(+) and E1<--B1 transitions were recorded indicating the existence of two, well defined minima in the E1-state potential energy (PE) curve. First, considerably deep, with the well depth of D(e)'(E1(2))=1309.0 cm(-1) and second, separated by a positive PE barrier, with D(e)'(E1(2))=24.2 cm(-1). Combination of bound-bound and first-time observed bound-free excitation spectra enabled a complete determination of the spectroscopical parameters of the PE curve of the E1-Rydberg state, the height of the PE barrier and its approximate location. In the excitation spectra of the E1<--B1 transition, a nodal structure of the bound-free transitions was observed and elucidated by a projection of the B1-state vibrational wave-functions onto the E1-state potential barrier and/or onto the repulsive part of the E1-state PE curve. The experimental results of our investigation coincides well with recently published results of ab initio calculation of Czuchaj and co-workers [Chem. Phys. 248 (1999) 1; Chem Phys. 263 (2001) 7; Theor. Chem Acc. 105 (2001) 219].

Laser spectroscopy of CdKr molecules in ultraviolet region

Excitation spectra of the A0+(5(3)P1)<--X0+(5(1)S0), B1(5(3)P1)<--X0+ and D1(5(1)P1)<--X0+ transitions as well as a fluorescence spectrum of the D1(v') = 16 --> X0+ transition in CdKr van der Waals molecule has been recorded in an experiment of a continuous supersonic molecular beam crossed with a pulsed dye laser beam. A rigorous analysis of the excitation spectra based on Birge-Sponer and LeRoy-Bernstein methods aided with a computer calculation, utilizing a program of near dissociation expansion lead to the X0+- and improved A0+-, B1- and D1-state characterizations. Evidence of a theoretically predicted potential barrier within the B1-state well was found and discussed with regard to the latest result of ab initio calculation. An analysis of bound-bound and bound-free parts of the fluorescence spectrum confirmed a v'-assignment and indicated that Morse and Maitland-Smith M-S (n0, n1) functions are adequate representations of the bound well and repulsive wall of the X0+-state potential energy curve, respectively. All spectroscopic characteristics obtained in this work are compared with newest theoretical studies of this complex.

Double-well potential energy curve of cadmium-krypton molecule in the B1(5(3)P1) excited state

The real shape of a double-well B1(5(3)P1)-state potential in CdKr van der Waals molecule was reconstructed applying both the experimental data, using a Birge-Sponer method-based analysis of the B1 <-- X0+(5(1)S0) transition in excitation spectrum, and theoretical result of recent ab initio calculation. An inverse perturbation approach method was used for defining an accurate B1-state potential energy curve.

Laser excitation spectrum and spectroscopic potential parameters of Cd2 molecule in the 1u(5(3)P2) energy state

Excitation spectrum of Cd2 van der Waals complex was observed in a supersonic free-jet expansion beam. Cadmium dimers were seeded in argon environment (a carrier gas) while a pulsed dye laser served as an excitation light source. Well resolved structures of vibrational bands arising from transition between 1u(3pi(u)) and X0g+ (1sigmag+) states were observed. Using a Birge-Sponer method for analyzing the vibrational excitation spectrum, the first-time determination of the spectroscopical potential parameters of the 1u molecular state was performed. We obtained D'e = 723 +/- 10 cm(-1), omega'e = 28.9 +/- 1.0 cm(-1), omega'e x'e = 0.260 +/- 0.002 cm(-1) and R'e = 3.93 +/- 0.05 A. The latter value was estimated with the help of the computer-simulation of the spectrum. The results are compared with recent results of ab initio calculation of Czuchaj et al. (Chem. Phys. Lett. 225 (1994) 233) and demonstrate a reasonable agreement.

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

Few patients with Behçet's syndrome have gastrointestinal ulceration. Such patients are difficult to treat and have a higher mortality. Faced with refractory symptoms in two patients with intestinal Behçet's, we used the tumour necrosis factor alpha (TNF-alpha) monoclonal antibody infliximab to induce remission. Both women (one aged 27 years, the other 30 years) presented with orogenital ulceration, pustular rash, abdominal pain, bloody diarrhoea due to colonic ulceration, weight loss, and synovitis. One had thrombophlebitis, digital vasculitis, perianal fistula, and paracolic abscess; the other had conjunctivitis and an ulcer in the natal cleft. Treatment with prednisolone, methyl prednisolone, and thalidomide in one and prednisolone, colchicine, and cyclosporin in the other was ineffective. After full discussion, infliximab (3 mg/kg, dose reduced because of recent sepsis in one, and 5 mg/kg in the other) was administered. Within 10 days the ulcers healed, with resolution of bloody diarrhoea and all extraintestinal manifestations. A second infusion of infliximab was necessary eight weeks later in one case, followed by sustained (>15 months) remission on low dose thalidomide. Remission was initially sustained for 12 months in the other but thalidomide had to be stopped due to intolerance, and a good response to retreatment lasted only 12 weeks without immunosuppression, before a third infusion. The cause of Behçet's syndrome is unknown but peripheral blood CD45 gammadelta T cells in Behçet's produce >50-fold more TNF-alpha than controls when stimulated with phorbol myristate acetate and anti-CD3. Infliximab could have a role for inducing remission in Behçet's syndrome.

Interatomic potentials of cadmium-argon B1(3sigma+) and X0+(1sigma+) states based on near-dissociation expansion and 'hot' bands observed in the B1 <-- X0+ excitation spectrum

B1(3sigma+) <-- X0+(1sigma+) excitation spectrum of the cadmium-argon van der Waals molecule has been recorded in the experiment of a continuous supersonic molecular beam crossed with a pulsed dye laser beam. The B1-state dissociation energy was directly observed and a long-range behavior of the B1-state intermolecular potential was derived using a near-dissociation expansion procedure of LeRoy and Bernstein. A first-time direct determination of the X0+ ground state characteristics based on 'hot' bands observed is presented as well. The new result is compared with other experimental and theoretical reports available in the literature.

Generation and characterization of an anti-idiotypic antibody specific for intercellular adhesion molecule-1

Intercellular adhesion molecule-1 (ICAM-1) is an inducible ligand for the LFA-1/MAC-1 family of leukocyte adhesion molecules. The results reported herein show that a mouse monoclonal anti-idiotypic antibody, CA3, specific for R6.5 anti-ICAM-1 mAb, shares conformational homology with the original epitope bound by R6.5. The CA3 bound specifically to R6.5 F(ab) fragments and blocked the binding of R6.5 to its ICAM-1 epitope; no CA3 binding was detected to a second anti-ICAM-1 mAb F(ab) fragment nor to control mouse IgG F(ab) fragments. Similarly, the interaction of CA3 with R6.5 was inhibited by sICAM-1. However, CA3 was ineffective in inhibiting CD18-dependent cell aggregation. A rabbit anti-CA3 response (Ab3) further indicated that CA3 is of the Ab2 beta type. Significant binding of anti-CA3 to sICAM-1 was demonstrated and anti-CA3 competed with R6.5 for binding to sICAM-1. Anti-CA3 bound to both soluble and cell-surface-associated ICAM-1. However, unlike R6.5, significant binding both to reduced sICAM-1 and to native sICAM-1 was exhibited by anti-CA3, whereas the binding of R6.5 to reduced sICAM-1 was undetectable.

A form of circulating ICAM-1 in human serum

A circulating form of the usually membrane-bound intercellular adhesion molecule-1 (ICAM-1) was identified and characterized in normal human serum, and in sera from patients with leukocyte adhesion deficiency (LAD). The molecule, designated circulating ICAM-1 (cICAM-1) was detected and quantitated by sandwich ELISA. Levels of cICAM-1 in sera from normal individuals ranged from 100 to 200 ng/ml. Sera from LAD patients had elevated cICAM-1 levels ranging from 200 to 700 ng/ml. The elevated levels of cICAM-1 in LAD sera may be due to an inability to adsorb cICAM-1 to cell-bound LFA-1 or may be an indirect result of the pathology accompanying the syndrome. cICAM-1 bound to mAb specific for four distinct ICAM-1 epitopes localized in domains D1, D2, D4, and D5, and displayed similar molecular size properties as recombinant soluble ICAM-1 on FPLC size-exclusion chromatography. When immobilized via a domain D5-specific mAb, cICAM-1 mediated function (LFA-1)-dependent lymphocyte adhesion equivalent to sICAM-1. These data indicate that cICAM-1 contains most, if not all, of the five extracellular domains of membrane ICAM-1, as well as the ability to bind specifically to LFA-1. The cellular source of cICAM-1 appeared to be from mononuclear cells; only lymphoid cell lines or primary PBMC cultures had detectable levels of cICAM-1 in cell culture supernatants. Because cICAM-1 retains the ability to bind specifically to LFA-1, it may act to regulate cell adhesion by promoting de-adhesion. Alternatively, cICAM-1 may be the indirect consequence of inflammation or tissue damage. As such, the detection of cICAM-1 could be useful as a marker of inflammatory disease.

A form of circulating ICAM-1 in human serum

A circulating form of the usually membrane-bound intercellular adhesion molecule-1 (ICAM-1) was identified and characterized in normal human serum, and in sera from patients with leukocyte adhesion deficiency (LAD). The molecule, designated circulating ICAM-1 (cICAM-1) was detected and quantitated by sandwich ELISA. Levels of cICAM-1 in sera from normal individuals ranged from 100 to 200 ng/ml. Sera from LAD patients had elevated cICAM-1 levels ranging from 200 to 700 ng/ml. The elevated levels of cICAM-1 in LAD sera may be due to an inability to adsorb cICAM-1 to cell-bound LFA-1 or may be an indirect result of the pathology accompanying the syndrome. cICAM-1 bound to mAb specific for four distinct ICAM-1 epitopes localized in domains D1, D2, D4, and D5, and displayed similar molecular size properties as recombinant soluble ICAM-1 on FPLC size-exclusion chromatography. When immobilized via a domain D5-specific mAb, cICAM-1 mediated function (LFA-1)-dependent lymphocyte adhesion equivalent to sICAM-1. These data indicate that cICAM-1 contains most, if not all, of the five extracellular domains of membrane ICAM-1, as well as the ability to bind specifically to LFA-1. The cellular source of cICAM-1 appeared to be from mononuclear cells; only lymphoid cell lines or primary PBMC cultures had detectable levels of cICAM-1 in cell culture supernatants. Because cICAM-1 retains the ability to bind specifically to LFA-1, it may act to regulate cell adhesion by promoting de-adhesion. Alternatively, cICAM-1 may be the indirect consequence of inflammation or tissue damage. As such, the detection of cICAM-1 could be useful as a marker of inflammatory disease.

Granulocyte migration ability in subjects hypersensitive to aspirin

The reported study was carried out on 32 patients with atopic asthma. Twenty-seven patients had atopic asthma and were hypersensitive to aspirin. Twenty patients were hypersensitive only to aspirin. At the time of the investigation the patients were in the remission period at the beginning of the investigations and the lowest aspirin dose producing hypersensitivity symptoms was established in each case. It ranged from 0.05 to 0.5 g. In the group of patients hypersensitive to aspirin were included those in whom spirometric measurements demonstrated a FEV1 fall below 20% of the initial level. In all the patients and controls studied the "in vitro" granulocyte migration test was done by Clausen's method and "in vivo" by Southam's method. As shown in the presented results, patients with aspirin hypersensitivity have a defect in the migration of granulocytes of the vascular and tissue pools.

Kinetics and characterization of intercellular adhesion molecule-1 (ICAM-1) expression on keratinocytes in various inflammatory skin lesions and malignant cutaneous lymphomas

The kinetics of expression of the intercellular adhesion molecule-1 (ICAM-1) were studied on keratinocytes in skin biopsy specimens of sensitive persons in whom the haptens were applied in a standardized format for allergic contact dermatitis testing. There was no ICAM-1 expressed on keratinocytes of normal skin; ICAM-1 was induced as early as 4 hours after the application of the patch in some subjects. By 48 hours after the application of the patch, all specimens contained ICAM-1-positive keratinocytes. This was concurrent with a heavy mononuclear cell dermal infiltrate and maximum clinical manifestations. Expression of human lymphocyte antigen (HLA)-DR or other inducible surface proteins on keratinocytes under these conditions was much less frequent. When specimens from primary irritant dermatitis were used, only 1 of 14 cases had keratinocytes expressing ICAM-1 at 48 hours, the time of maximum clinical manifestation. Among benign inflammatory lesions, most cases resembled the allergic patch test specimens in that ICAM-1 was expressed to a large degree on keratinocytes. Again, the expression of HLA-DR was variable. Malignant skin lesions, on the other hand, were much less consistent and generally lower in terms of ICAM-1 expression on keratinocytes. Furthermore, in contrast to the benign cutaneous conditions, some malignant skin lesions contained keratinocytes that expressed class II antigens or other inducible surface proteins in the absence of ICAM-1. These data suggest that ICAM-1 plays a role in the specific immune response by facilitating either antigen presentation or lymphocytic infiltration.

[The most frequent complications during long-term corticotherapy]

In 274 outpatients with chronic spastic bronchitis long-term treatment with corticosteroids was used due to their clinical condition. In patients treated for 6 years with daily doses of 1-2 mg of prednisolone no corticosteroid-induced complications were observed. Transient ecchymoses occurred in patients treated for longer time periods with prednisolone 4 mg daily. In 12.5% of patients pityriasis versicolor developed, and muscle weakness was the complaint in 3.1% of cases. In patients treated with 6 mg daily of prednisolone petechiae were noted in 35% of cases, in 10% subcutaneous tissue atrophy, in 2.5% osteoporosis was observed, and menstruation disturbances were reported in 25% of the treated women. In patients receiving prednisolone 8 mg daily subcutaneous extravasations developed in 80% of cases, skin atrophy in 50%, myopathy in 25%, crural thrombophlebitis in 5%, cushingoid features in 7.5%. In patients receiving prednisolone 12 mg daily, besides the above complications, fractures occurred in 14.2% of cases, and psychotic symptoms in 7%.

Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies

The expression of intercellular adhesion molecule-1 (ICAM-1) on primary human fibroblasts, a human fibrosarcoma, chondrosarcoma, and adenocarcinoma cell line in response to IL-1, TNF-alpha, or IFN-gamma was studied using an ELISA with anti-ICAM-1 mAb. The induction of ICAM-1 by these cytokines was neutralized by cytokine-specific antisera as well as some steroids and the glycosylation inhibitor, tunicamycin. Cyclohexamide up-regulated the expression of ICAM-1 on chondrosarcoma cells but had little or no effect on carcinoma cells. These data indicate different mechanisms in the regulation and expression of ICAM-1 on the various cell types and provide some insight into the anti-inflammatory effects of some pharmacologic agents.

Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies

The expression of intercellular adhesion molecule-1 (ICAM-1) on primary human fibroblasts, a human fibrosarcoma, chondrosarcoma, and adenocarcinoma cell line in response to IL-1, TNF-alpha, or IFN-gamma was studied using an ELISA with anti-ICAM-1 mAb. The induction of ICAM-1 by these cytokines was neutralized by cytokine-specific antisera as well as some steroids and the glycosylation inhibitor, tunicamycin. Cyclohexamide up-regulated the expression of ICAM-1 on chondrosarcoma cells but had little or no effect on carcinoma cells. These data indicate different mechanisms in the regulation and expression of ICAM-1 on the various cell types and provide some insight into the anti-inflammatory effects of some pharmacologic agents.

Membrane-associated interleukin 1 activity on human U937 tumor cells: stimulation of PGE2 production by human chondrosarcoma cells

Membrane-associated interleukin 1 (IL 1) activity was induced on the human macrophage tumor cell line, U937, by pretreatment with phorbol myristic acid (PMA). Incubation of PMA-treated, paraformaldehyde-fixed U937 cells with the murine cell line D10.G4.1 in the presence of concanavalin A caused an increase in DNA synthesis as measured by the uptake of tritiated thymidine. Paraformaldehyde-fixed U937, not pretreated with PMA, showed little or no activity. A rabbit polyclonal antibody directed against human IL 1 neutralized all membrane-associated IL 1-like activity, as measured by the inhibition of D10.G4.1 cell proliferation. PMA-treated U937 caused a pronounced enhancement of PGE2 production from a human chondrosarcoma cell line, SW-1353. Membrane-associated IL 1 induced a more potent PGE2 response than did a maximal concentration of soluble IL 1. Rabbit antihuman IL 1 neutralized membrane-bound IL 1 induction of PGE2. The data presented here raise the possibility that membrane-bound IL 1 may play a primary role in the pathophysiology of the inflammatory disease process.

Membrane-associated interleukin 1 activity on human U937 tumor cells: stimulation of PGE2 production by human chondrosarcoma cells

Membrane-associated interleukin 1 (IL 1) activity was induced on the human macrophage tumor cell line, U937, by pretreatment with phorbol myristic acid (PMA). Incubation of PMA-treated, paraformaldehyde-fixed U937 cells with the murine cell line D10.G4.1 in the presence of concanavalin A caused an increase in DNA synthesis as measured by the uptake of tritiated thymidine. Paraformaldehyde-fixed U937, not pretreated with PMA, showed little or no activity. A rabbit polyclonal antibody directed against human IL 1 neutralized all membrane-associated IL 1-like activity, as measured by the inhibition of D10.G4.1 cell proliferation. PMA-treated U937 caused a pronounced enhancement of PGE2 production from a human chondrosarcoma cell line, SW-1353. Membrane-associated IL 1 induced a more potent PGE2 response than did a maximal concentration of soluble IL 1. Rabbit antihuman IL 1 neutralized membrane-bound IL 1 induction of PGE2. The data presented here raise the possibility that membrane-bound IL 1 may play a primary role in the pathophysiology of the inflammatory disease process.